Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 1—January 2012


Mycobacterium riyadhense Pulmonary Infection, France and Bahrain

Sylvain GodreuilComments to Author , Hélène Marchandin, Anne-Laure Michon, Mikael Ponsada, Georges Chyderiotis, Patrick Brisou, Abdul Bhat, and Gilles Panteix
Author affiliations: Institut National de la Santé et de la Recherche Médicale Unité 1058, Montpellier, France (S. Godreuil); Hôpital Arnaud de Villeneuve, Montpellier (S. Godreuil, H. Marchandin, A.-L. Michon); Université Montpellier 1, Montpellier (H. Marchandin, A.-L. Michon); Laboratoire Biomnis, Lyon, France (M. Ponsada, G. Chyderiotis, G. Panteix); Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France (P. Brisou); Awali Hospital, Awali, Bahrain (A. Bhat)

Main Article


Clinical characteristics, drug susceptibility testing, and outcome for 3 case-patients with Mycobacterium riyadhense infection, France and Bahrain*

Patient age, y/sex Clinical situation Molecular-based identification of M. riyadhense
Drug susceptibility pattern, drug (MIC, µg/mL) interpretation Antimicrobial drug therapy Treatment duration, outcome
Gene % Sequence similarity with type strain GenBank accession nos.
Bone infection in left maxillary sinus
16S rRNA, rpoB, hsp65
Type strain
EU27464, FJ786256, EU921671
AMK (10.0) R; CYC (20.0) S; CIP (2.0) S; CLF (<0.5) S; CLR (<2.0) S; EMB (5.0) S; INH (1.0) I; PAS (>1.0) R; PRO (<1.0) S; RFB (0.2) S; RIF (0.2) S; STR (5.0) S‡
9 mo, cured
Pulmonary infection
16S rRNA¶, rpoB, hsp65
99.8, 99.8, 100
JF896094, JF896096, JF896098
AMK (<1.0) S; CIP (1.0) S; CLR (0.12) S; DOX (16.0) R; EMB (<0.5) S; ETH (0.3) S; INH (0.5) S; LZD (<1.0) S; MOX (<0.12) S; RFB (<0.25) S; RIF (<0.12) S; STR (1.0) S; TMP/SMX (<0.12/2.38) NA#
1 y, cured
43/M** Pulmonary infection 16S rRNA¶, rpoB, hsp65 99.8, 99.7, 99.1 JF896095, JF896097, JF896099 AMK (<1.0) S; CIP (0.12) S; CLR (0.12) S; EMB (<0.5) S; ETH (0.3) S; DOX (4.0) R; INH (0.25) S; LZD (<1.0) S; MOX (<0.12) S; RFB (<0.25) S; RIF (<0.12) S; STR (<0.5) S; TMP/SMX (<2.0/38.0) NA# CLR, CIP; then INH, RFP, EMB, PZA, CLR, CIP; then INH, RFP, CLR, CIP 1 y, relapse; 8 mo, cured

*AMK, amikacin; R, resistant; CYC, cycloserine; S, susceptible; CIP, ciprofloxacin; CLF, clofazimine; CLR, clarithromycin; EMB, ethambutol; INH, isoniazid; I, intermediate; PAS, para-aminosalicylate sodium; PRO, prothionamide; RFB, rifabutin; RIF, rifampin; STR, streptomycin ; RFP, rifapentine; DOX, doxycycline; ETH, ethionamide; LZD, linezolid; MOX, moxifloxacin; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not available; PZA, pyrazinamide.
†Patient in Saudi Arabia; reported by van Ingen et al. (1).
‡Drug susceptibility testing was performed by using the agar dilution method.
§Patient in France.
¶Low 16S rRNA gene polymorphism between several mycobacterial species.
#Drug susceptibility testing was performed by using broth microdilution panels (SLOMYCO Sensititer; Trek Diagnosis Systems, Cleveland< OH, USA) and interpreted according to standards of the National Committee for Clinical Laboratory Standards (3).
**Patient in Bahrain.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO